CCG215022|1813527-81-9|-陌孚医药/Medlife

您当前的位置：

CCG215022

目录号: PL09868 纯度: ≥98%

CAS No. :1813527-81-9

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	CCG215022
中文别名	GRK抑制剂(CCG215022);CCG-215022游离态;化合物CCG215022;4-(4-氟-3-((吡啶-2-基甲基)氨基甲酰基)苯基)-N-(1H-吲唑-5-基)-6-甲基-2-氧代-1,2,3,4-四氢嘧啶-5-甲酰胺
英文名称	CCG215022
英文别名	CCG215022;CCG-215022;4-(4-fluoro-3-((pyridin-2-ylmethyl)carbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide;CCG215;BCP18562;BDBM50173310;AK685751;4-[4-fluoro-3-(pyridin-2-ylmethylcarbamoyl)phenyl]-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide;CID 118888941;CS-2782;CCG 215022;5-Pyrimidinecarboxamide, 4-[4-fluoro-3-[[(2-pyridinylmethyl)amino]carbonyl]phenyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-;4-(4-Fluoro-3-((pyridin-2-ylmethyl)carbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide;PKA,CCG215022,CCG-215022,Inhibitor,Protein kinase A,CCG 215022,inhibit
Cas No.	1813527-81-9
分子式	C₂₆H₂₂FN₇O₃
分子量	499.50
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	CCG215022 是一种G蛋白偶联受体激酶 (GRK) 抑制剂，作用于 GRK2，GRK5 和 GRK1，IC₅₀ 分别为 0.15±0.07 μM，0.38±0.06 μM 和 3.9±1 μM。
生物活性	CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC 50 s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for GRK2, GRK5 and GRK1, respectively.
性状	Solid
IC50 & Target[1][2]	IC50 & Target: 3.9±1.0 μM (GRK1), 0.15±0.07 μM (GRK2), 0.38±0.06 μM (GRK5), 120±40 μM (PKA)
体外研究(In Vitro)	CCG215022 has nanomolar potency against both GRK2 and GRK5 and is at least 20-fold more potent than Paroxetine. In the course of a GRK2 structure-based drug design campaign, CCG215022 exhibits nanomolar IC50 values against both GRK2 and GRK5 and good selectivity against other closely related kinases such as GRK1 and PKA. Treatment of murine cardiomyocytes with CCG215022 results in significantly increases contractility at 20-fold lower concentrations than Paroxetine, an inhibitor with more modest selectivity for GRK2. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Homan KT, et al. Crystal Structure of G Protein-coupled Receptor Kinase 5 in Complex with a Rationally DesignedInhibitor. J Biol Chem. 2015 Aug 21;290(34):20649-59.

溶解度数据	In Vitro: DMSO : ≥ 28 mg/mL (56.06 mM)配制储备液

搜索质检报告(COA)

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品